Tracking a Shape-Shifting Cancer: How IDH-Mutant Gliomas Evolve After Treatment
Summary
- Sylvester Comprehensive Cancer Center researchers traced how IDH-mutant gliomas evolve after treatment.
- The study reveals why tumors recur despite therapy.
- Findings point to new strategies for precision cancer care.
At first glance, IDH-mutant gliomas can appear deceptively calm. They often grow slowly, affecting adults in the prime of their lives. Many patients respond well to surgery, radiation or chemotherapy. But like embers buried beneath ash, these tumors almost always return.
A new, multi-institutional study led in part by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, shows why.
By following tumors over time at an unprecedented molecular resolution, scientists mapped how IDH-mutant gliomas change as they recur. The work reveals a dynamic landscape shaped by genetics, epigenetics and the tumor’s surrounding immune environment. The work, published in Nature, offers a clearer picture of how these brain cancers adapt under pressure and how that adaptation may guide future patient care.
“This study allowed us to see tumor evolution as a process, not a snapshot,” said Antonio Iavarone, M.D., director of the Sylvester Brain Tumor Institute (SBTI), deputy director of Sylvester and co-senior author of the study.
Dr. Iavarone collaborated with co-first author Luciano Garofano, Ph.D., an assistant professor in the Bioinnovation and Genome Sciences Division at the Translational Genomics Research Institute (TGen), part of City of Hope, in Phoenix, Arizona.
“By tracking how these tumors change over time, we can begin to understand why treatments stop working and how cancer cells adapt to survive. That knowledge is critical to designing therapies that stay one step ahead of the disease,” said Dr. Iavarone, a professor of neurological surgery, biochemistry and molecular biology at the Miller School.
Watching Cancer Evolve, Cell by Cell
Using advanced, single-nucleus sequencing technologies, researchers analyzed 75 tumor samples collected at different time points from 35 patients. Like time-lapse photography compressed into data, the approach captured how individual cancer cells shifted their identity as disease progressed. Some cells became more stem-like and proliferative. Others adopted stress-response programs. Many lost the hallmarks of normal brain cell differentiation.
One of the clearest signals was a gradual shift toward a more primitive, stem-like state. As tumors recurred, they became less differentiated and more aggressive, especially when new genetic alterations emerged after treatment. These changes were not random. They followed recognizable patterns, resembling stages of normal brain development gone awry.
Tumors behaved less like static masses and more like shape-shifters, adjusting their forms to survive.
When Genetics is Not the Whole Story
DNA mutations alone were not the only driver of the changes. The team found that tumors also change in response of their surroundings. They noted that, as a tumor recurred, more cancer cells shifted into a tougher, more aggressive mode that is often seen when tissue is injured or inflamed. This happened even when no new DNA changes were detected. That shift went hand in hand with changes in nearby immune cells, especially macrophages, which are cells involved in inflammation and repair.
“It’s a reminder that cancer does not evolve in isolation,” said Anna Lasorella, M.D., director of the Precision Medicine Initiative at Sylvester, SBTI co-director and co-senior author of the study.
“Tumor cells are constantly responding to signals from the surrounding tissue and immune system, especially after treatment. By understanding how those interactions push cancer into more aggressive states, we can begin to develop therapies that target not only the tumor itself, but the environment that helps it resist treatment,” said Dr. Lasorella, also a professor of biochemistry and molecular biology at the Miller School,.
This dual influence of intrinsic genetics and extrinsic immune signals helps explain why standard treatments can lose effectiveness over time. Radiation and chemotherapy may suppress one population of tumor cells while inadvertently creating conditions that favor another, more resilient state.
What These Discoveries Mean for Patients
For translational research, these insights matter.
Understanding which cell states dominate a tumor at diagnosis or recurrence could eventually inform treatment decisions, much like biomarkers guide therapy in breast or lung cancer. Tumors enriched with stem-like, proliferative cells may benefit from strategies that promote differentiation, nudging cancer cells into a less aggressive identity. Others may require approaches that target inflammatory signaling or immune interactions that fuel resistance.
The findings also help contextualize emerging therapies, including mutant IDH inhibitors. Early clinical studies have shown that these drugs can push tumor cells toward differentiation, but responses vary. This research suggests why. Genetic alterations acquired over time may blunt that effect, while microenvironmental pressures steer tumors down alternative paths.
Timing and the Path Forward
From a patient-care perspective, the study reinforces the importance of timing. Intervening earlier, before resistant cell states take hold, may offer a better chance to alter the cancer’s trajectory. It also underscores the value of repeat sampling and longitudinal monitoring, an approach increasingly feasible as molecular diagnostics advance. Following tumors over time reveals turning points and vulnerabilities that would otherwise remain hidden.
At Sylvester, where laboratory discovery and clinical care intersect by design, especially at the 12-story Kenneth C. Griffin Cancer Research Building, which brings laboratory science, clinical trials and wellness spaces under one roof, these insights help bridge the gap between bench and bedside. By decoding how tumors evolve, researchers are laying the groundwork for therapies that anticipate resistance rather than react to it.
“IDH-mutant gliomas may be persistent, but they are no longer incomprehensible,” said Dr. Iavarone. “And with every layer uncovered, we move closer to treatments for our patients that are as adaptive and precise as cancer itself.”
More from Sylvester Comprehensive Cancer Center
Dr. Macarena de la Fuente shares how clinical trials and targeted therapies at Sylvester Brain Tumor Institute are improving brain cancer care.
A new drug tested at Sylvester Comprehensive Cancer Center is generating encouraging results for patients with low-grade gliomas.
Dr. Macarena de la Fuente envisions a future that empowers patients to manage tumors with fewer compromises.
A new study on the drug, olutasidenib, finds it to be an effective treatment in nearly half of tested glioma patients.
Tags: brain cancer, cancer research, chemotherapy, Dr. Anna Lasorella, Dr. Antonio Iavarone, glioma, gliomas, Newsroom, Radiation oncology, Sylvester Comprehensive Cancer Center